scholarly journals Mesenchymal Stem Cells in COVID-19: A Journey from Bench to Bedside

2020 ◽  
Vol 52 (1) ◽  
pp. 24-35
Author(s):  
Kamal Kant Sahu ◽  
Ahmad Daniyal Siddiqui ◽  
Jan Cerny

Abstract The COVID-19 pandemic has led to a major setback in both the health and economic sectors across the globe. The scale of the problem is enormous because we still do not have any specific anti-SARS-CoV-2 antiviral agent or vaccine. The human immune system has never been exposed to this novel virus, so the viral interactions with the human immune system are completely naive. New approaches are being studied at various levels, including animal in vitro models and human-based studies, to contain the COVID-19 pandemic as soon as possible. Many drugs are being tested for repurposing, but so far only remdesivir has shown some positive benefits based on preliminary reports, but these results also need further confirmation via ongoing trials. Otherwise, no other agents have shown an impactful response against COVID-19. Recently, research exploring the therapeutic application of mesenchymal stem cells (MSCs) in critically ill patients suffering from COVID-19 has gained momentum. The patients belonging to this subset are most likely beyond the point where they could benefit from an antiviral therapy because most of their illness at this stage of disease is driven by inflammatory (over)response of the immune system. In this review, we discuss the potential of MSCs as a therapeutic option for patients with COVID-19, based on the encouraging results from the preliminary data showing improved outcomes in the progression of COVID-19 disease.

2021 ◽  
Vol 22 (5) ◽  
pp. 2269
Author(s):  
Keiji Masuda ◽  
Xu Han ◽  
Hiroki Kato ◽  
Hiroshi Sato ◽  
Yu Zhang ◽  
...  

A subpopulation of mesenchymal stem cells, developmentally derived from multipotent neural crest cells that form multiple facial tissues, resides within the dental pulp of human teeth. These stem cells show high proliferative capacity in vitro and are multipotent, including adipogenic, myogenic, osteogenic, chondrogenic, and neurogenic potential. Teeth containing viable cells are harvested via minimally invasive procedures, based on various clinical diagnoses, but then usually discarded as medical waste, indicating the relatively low ethical considerations to reuse these cells for medical applications. Previous studies have demonstrated that stem cells derived from healthy subjects are an excellent source for cell-based medicine, tissue regeneration, and bioengineering. Furthermore, stem cells donated by patients affected by genetic disorders can serve as in vitro models of disease-specific genetic variants, indicating additional applications of these stem cells with high plasticity. This review discusses the benefits, limitations, and perspectives of patient-derived dental pulp stem cells as alternatives that may complement other excellent, yet incomplete stem cell models, such as induced pluripotent stem cells, together with our recent data.


Biomolecules ◽  
2020 ◽  
Vol 10 (9) ◽  
pp. 1306
Author(s):  
Ann-Kristin Afflerbach ◽  
Mark D. Kiri ◽  
Tahir Detinis ◽  
Ben M. Maoz

The human-relevance of an in vitro model is dependent on two main factors—(i) an appropriate human cell source and (ii) a modeling platform that recapitulates human in vivo conditions. Recent years have brought substantial advancements in both these aspects. In particular, mesenchymal stem cells (MSCs) have emerged as a promising cell source, as these cells can differentiate into multiple cell types, yet do not raise the ethical and practical concerns associated with other types of stem cells. In turn, advanced bioengineered in vitro models such as microfluidics, Organs-on-a-Chip, scaffolds, bioprinting and organoids are bringing researchers ever closer to mimicking complex in vivo environments, thereby overcoming some of the limitations of traditional 2D cell cultures. This review covers each of these advancements separately and discusses how the integration of MSCs into novel in vitro platforms may contribute enormously to clinical and fundamental research.


2015 ◽  
Vol 2015 ◽  
pp. 1-13 ◽  
Author(s):  
John Michel ◽  
Matthew Penna ◽  
Juan Kochen ◽  
Herman Cheung

Modern day tissue engineering and cellular therapies have gravitated toward using stem cells with scaffolds as a dynamic modality to aid in differentiation and tissue regeneration. Mesenchymal stem cells (MSCs) are one of the most studied stem cells used in combination with scaffolds. These cells differentiate along the osteogenic lineage when seeded on hydroxyapatite containing scaffolds and can be used as a therapeutic option to regenerate various tissues. In recent years, the combination of hydroxyapatite and natural or synthetic polymers has been studied extensively. Due to the interest in these scaffolds, this review will cover the wide range of hydroxyapatite containing scaffolds used with MSCs forin vitroandin vivoexperiments. Further, in order to maintain a progressive scope of the field this review article will only focus on literature utilizing adult human derived MSCs (hMSCs) published in the last three years.


2021 ◽  
Vol 12 ◽  
Author(s):  
Isabelle Serr ◽  
Maria Kral ◽  
Martin G. Scherm ◽  
Carolin Daniel

Immunodeficient mice engrafted with a functional human immune system [Human immune system (HIS) mice] have paved the way to major advances for personalized medicine and translation of immune-based therapies. One prerequisite for advancing personalized medicine is modeling the immune system of individuals or disease groups in a preclinical setting. HIS mice engrafted with peripheral blood mononuclear cells have provided fundamental insights in underlying mechanisms guiding immune activation vs. regulation in several diseases including cancer. However, the development of Graft-vs.-host disease restrains relevant long-term studies in HIS mice. Alternatively, engraftment with hematopoietic stem cells (HSCs) enables mimicking different disease stages, however, low frequencies of HSCs in peripheral blood of adults impede engraftment efficacy. One possibility to overcome those limitations is the use of patient-derived induced pluripotent stem cells (iPSCs) reprogrammed into HSCs, a challenging process which has recently seen major advances. Personalized HIS mice bridge research in mice and human diseases thereby facilitating the translation of immunomodulatory therapies. Regulatory T cells (Tregs) are important mediators of immune suppression and thereby contribute to tumor immune evasion, which has made them a central target for cancer immunotherapies. Importantly, studying Tregs in the human immune system in vivo in HIS mice will help to determine requirements for efficient Treg-targeting. In this review article, we discuss advances on personalized HIS models using reprogrammed iPSCs and review the use of HIS mice to study requirements for efficient targeting of human Tregs for personalized cancer immunotherapies.


Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 5976-5976
Author(s):  
Hwan-Young Kim ◽  
Ji-Eun Noh ◽  
Hee-Jo Baek ◽  
Jae-Dong Moon ◽  
Jong-Hee Shin ◽  
...  

Abstract Background: Fluoranthene is a member of the polycyclic aromatic hydrocarbon family, comprising ubiquitous environmental pollutants and potent mutagens. Fluoranthene has been classified by the International Agency for Research on Cancer as a group 3 carcinogens, whose carcinogenicity has not been fully determined in humans. Moreover, the stem cell toxicity and global hematotoxicity associated with fluoranthene exposure have not been thoroughly studied in the bone marrow-mesenchymal stem cells (BM-MSCs). In this study, we determined whether fluoranthene-induced cellular responses could be used as biomarkers for the examination of BM-MSC dysfunction, and suggested the possible use of BM-MSCs for monitoring the acute hematotoxicity caused by environmental hazards. Materials and Methods: Apreviously published protocol was used for the isolation and characterization of BM-MSCs. Fluoranthene was added to the cell culture medium in the range of 25–500 µM. The cellular levels of hydrogen peroxide, indicating the presence of reactive oxygen species, were measured using an enzyme immunoassay. The mitochondrial mass, membrane potential, and mitochondrial DNA (mtDNA) copy number were measured using MitoTracker Green, MitoTracker Red probes, and real time PCR, respectively. A proteomic analysis of the mitochondrial-rich cytoplasmic fraction was performed using nano-LC-ESI-MS/MS, BioWorksBrowser, and the SEQUEST search engines. Quantitative mRNA and immunoblot measurements were used to further confirm the altered mRNA expression as well as to determine the levels of cellular proteins obtained from the proteomic analysis. Results: After exposure to fluoranthene, the BM-MSCs showed a marked reduction in cell number, and the viability decreased substantially after two days of exposure. BM-MSCs that were not treated with fluoranthene remained compact and spindle-shaped. These cells remained tightly attached to each other and to the substrate. In general, a direct exposure of fluoranthene depressed the proliferative capacity and altered the cell morphology of BM-MSCs. The cells detached from the subsurface, and cell-to-cell attachments were also lost. The viability significantly decreased after two days of fluoranthene exposure. The mtDNA copy number and the mass showed a rapid elevation after a 5-day exposure to fluoranthene. Hundreds of cellular proteins in the mitochondria-rich cytoplasmic fraction were markedly deregulated in cells treated with fluoranthene. The protein expression levels of poly [ADP-ribose] polymerase 1 (PARP-1), elongation factor 1-gamma, heat shock 70 kDa protein 1A/1B, heterogeneous nuclear ribonucleoproteins A2/B1 isoform B1, ATP-dependent RNA helicase DDX5, and T-complex protein 1 subunit theta were upregulated more than five-fold in cells treated with fluoranthene than in untreated cells. A significant (more than 2-fold) down-regulation in the cellular levels of the proteins myosin-9, protein ALO17 isoform 1, filamin-C isoform b, Na/K-transporting ATPase subunit alpha-1, nuclear pore membrane glycoprotein 210, and DNA-dependent protein kinase catalytic subunit isoform 2 was observed after a similar fluoranthene treatment. The presence of PARP-1 was further confirmed using mRNA analysis. Conclusion: This study investigated the global cellular responses after exposure to fluoranthene: PARP-1 was recognized as a notable biomarker for monitoring the PAH-induced hematotoxicity. In summary, BM-MSCs are promising candidates for the development of unique in vitro model systems for predicting fluoranthene-associated hematotoxicity and general toxicity in humans. Keywords: Fluoranthene, genotoxicity, hematotoxicity, bone marrow-mesenchymal stem cells Figure 1. Stem cell-based in vitro models and biomarkers for studying the hematotoxic effects of fluoranthene exposure. (A) Direct exposure of PAHs depressed the proliferative capacity of h-TERT cells with a thread-like or round shape and loose cell-to-cell attachment. (B) Cytotoxic effect of fluoranthene exposure to the bone marrow-mesenchymal stem cells remarkably increased with dose-dependent manner. (C) Identified potential biomarkers were categorized as their biological processes and molecular functions. (D) Immunoblot confirmed the increased expression of poly [ADP-ribose] polymerase 1 (PARP-1) after exposure of fluoranthene. Figure 1. Stem cell-based in vitro models and biomarkers for studying the hematotoxic effects of fluoranthene exposure. (A) Direct exposure of PAHs depressed the proliferative capacity of h-TERT cells with a thread-like or round shape and loose cell-to-cell attachment. (B) Cytotoxic effect of fluoranthene exposure to the bone marrow-mesenchymal stem cells remarkably increased with dose-dependent manner. (C) Identified potential biomarkers were categorized as their biological processes and molecular functions. (D) Immunoblot confirmed the increased expression of poly [ADP-ribose] polymerase 1 (PARP-1) after exposure of fluoranthene. Disclosures No relevant conflicts of interest to declare.


2021 ◽  
Vol 41 ◽  
pp. 616-632
Author(s):  
G Monaco ◽  
◽  
AJ El Haj ◽  
M Alini ◽  
MJ Stoddart

In vitro models aim to recapitulate the in vivo situation. To more closely mimic the knee joint environment, current in vitro models need improvements to reflect the complexity of the native tissue. High molecular weight hyaluronan (hMwt HA) is one of the most abundant bioactive macromolecules in healthy synovial fluid, while shear and dynamic compression are two joint-relevant mechanical forces. The present study aimed at investigating the concomitant effect of joint-simulating mechanical loading (JSML) and hMwt HA-supplemented culture medium on the chondrogenic differentiation of primary human bone-marrow-derived mesenchymal stem cells (hBM-MSCs). hBM-MSC chondrogenesis was investigated over 28 d at the gene expression level and total DNA, sulphated glycosaminoglycan, TGF-β1 production and safranin O staining were evaluated. The concomitant effect of hMwt HA culture medium and JSML significantly increased cartilage-like matrix deposition and sulphated glycosaminoglycan synthesis, especially during early chondrogenesis. A stabilisation of the hBM-MSC-derived chondrocyte phenotype was observed through the reduced upregulation of the hypertrophic marker collagen X and an increase in the chondrogenic collagen type II/X ratio. A combination of JSML and hMwt HA medium better reflects the complexity of the in vivo synovial joint environment. Thus, JSML and hMwt HA medium will be two important features for joint-related culture models to more accurately predict the in vivo outcome, therefore reducing the need for animal studies. Reducing in vitro artefacts would enable a more reliable prescreening of potential cartilage repair therapies.


Sign in / Sign up

Export Citation Format

Share Document